Supplementary Fig.S7 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors

<p>Supplementary Fig.S7 shows MTX-13 targets squamous cell carcinoma of lung, head and neck, esophagus and cervix</p>